<?xml version="1.0" encoding="UTF-8" standalone="yes"?><dealRecordsOutput><serviceExecutionTime>247</serviceExecutionTime><Deal id="123082"><Title>Bayer HealthCare to develop Ardea's MEK inhibitor series worldwide for cancer indications </Title><CompanyPrincipal id="17253">Ardea Biosciences Inc</CompanyPrincipal><CompanyPartner id="1003983">Bayer HealthCare AG</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Active</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="57.5" min="57.5"/><ValueProjected accuracy="&gt;" max="814.0" min="70.0"/></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"/><ValueProjected accuracy="Unknown" max="0.0" min="0.0"/></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1003783</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1003783</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="35.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1003783</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="35.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1003783</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1003783</Reference><Type>Royalty(%)</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1003783</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1160025</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1160025</Reference><Type>Sales Milestones</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1160025</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="372.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1160025</Reference><Type>Sales Milestones</Type><Value accuracy="Payment Unspecified"/></Payment><Payment><Reference>1160025</Reference><Type>Other Milestones</Type><Value accuracy="=&lt;"><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="372.0" usdExchangeRate="1.0" usdExchangeRatePeriod="2009 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1160025</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="Payment Unspecified"/></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="725">Solid tumor</Indication></Indications><ActionsPrimary><Action id="4762">MEK-1 protein kinase inhibitor</Action><Action id="4764">MEK-2 protein kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology></Technologies><DateStart>2009-04-28T00:00:00Z</DateStart><DateEventMostRecent>2016-03-31T00:00:00Z</DateEventMostRecent><Drugs><Drug id="59014"><DrugNameDisplay>RDEA-436</DrugNameDisplay><PhaseHighestStart id="CU">Clinical</PhaseHighestStart><PhaseHighestNow id="NDR">No Development Reported</PhaseHighestNow></Drug><Drug id="56559"><DrugNameDisplay>refametinib</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="C2">Phase 2 Clinical</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In April 2009, &lt;ulink linkType="Company" linkID="1003983"&gt;Bayer HealthCare&lt;/ulink&gt; signed an agreement with &lt;ulink linkType="Company" linkID="17253"&gt;Ardea Biosciences&lt;/ulink&gt; for worldwide development and commercialization rights to a series of mitogen-activated ERK kinase (MEK) inhibitors, which included lead candidates &lt;ulink linkType="Drug" linkID="56559"&gt;RDEA-119&lt;/ulink&gt; (BAY-86-9766) and &lt;ulink linkType="Drug" linkID="59014"&gt;RDEA-436&lt;/ulink&gt;,  for the treatment of solid tumors [&lt;ulink linkType="Reference" linkID="1003783"&gt;1003783&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1003934"&gt;1003934&lt;/ulink&gt;].   In January 2011, successful  initiation of a phase II  study of BAY 86-9766 in combination with &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;,  triggered a  milestone payment to Ardea [&lt;ulink linkType="Reference" linkID="1160025"&gt;1160025&lt;/ulink&gt;].   In May 2012, Ardea  earned  a milestone payment from Bayer,  triggered by the initiation of the phase II portion of a previously reported phase I/II clinical trial evaluating  BAY 86-9766 in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; for the treatment of advanced pancreatic cancer [&lt;ulink linkType="Reference" linkID="1296038"&gt;1296038&lt;/ulink&gt;]. In March 2016, Bayer discontinued the development of refametinib; returned rights to Ardea [&lt;ulink linkType="Reference" linkID="1757264"&gt;1757264&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1902853"&gt;1902853&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2016-03-31T00:00:00Z</Date><Drugs><DrugLink id="56559" nameDisplay="refametinib"/></Drugs><Summary>&lt;para&gt;- In March 2016, Bayer discontinued the development of refametinib; returned rights to Ardea [&lt;ulink linkType="Reference" linkID="1757264"&gt;1757264&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1902853"&gt;1902853&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Other Deal Update</Type></Event><Event><Date>2009-04-28T00:00:00Z</Date><Drugs><DrugLink id="56559" nameDisplay="refametinib"/><DrugLink id="59014" nameDisplay="RDEA-436"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1003783">1003783</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2009 Q1" exchangeRateUS="1">35</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="C2">Phase 2 Clinical</Stage><StageNotes>&lt;para&gt;RDEA119 is in Phase I as a single agent and in Phase I/II study in combination with Nexavar.&lt;/para&gt;</StageNotes><Summary>&lt;para&gt;In April 2009, &lt;ulink linkType="Company" linkID="1003983"&gt;Bayer HealthCare&lt;/ulink&gt; signed an agreement with &lt;ulink linkType="Company" linkID="17253"&gt;Ardea Biosciences&lt;/ulink&gt; for worldwide development and commercialization rights to a series of mitogen-activated ERK kinase (MEK) inhibitors, which included lead candidates &lt;ulink linkType="Drug" linkID="56559"&gt;RDEA-119&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="59014"&gt;RDEA-436&lt;/ulink&gt;,  for the treatment of solid tumors. Under the terms of the agreement, Bayer would have an exclusive, worldwide license to develop the MEK inhibitor series for all indications. The deal, worth up to $407 million excluding low double-digit royalties, included an upfront cash payment of $35 million for Ardea, as well as cash milestone payments. Ardea would be responsible for the completion of the phase I and phase II studies that were  being conducted for RDEA-119. Thereafter, Bayer would be responsible for the further development and commercialization of RDEA-119 and any of Ardea's other MEK inhibitors  [&lt;ulink linkType="Reference" linkID="1003783"&gt;1003783&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1003934"&gt;1003934&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2011-01-10T00:00:00Z</Date><Drugs><DrugLink id="56559" nameDisplay="refametinib"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1160025">1160025</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2010 Q4" exchangeRateUS="1">15</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In January 2011, initiation of a phase II  study of BAY-86-9766 in combination with &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; for hepatocellular carcinoma,  triggered a $15 million milestone payment to Ardea from Bayer HealthCare. Ardea would be eligible to receive up to an additional $357 million in milestones, including $7.5 million for initiating a second phase II trial of BAY 86-9766 for a different indication [&lt;ulink linkType="Reference" linkID="1160025"&gt;1160025&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Development Milestone</Type></Event><Event><Date>2012-05-30T00:00:00Z</Date><Drugs><DrugLink id="56559" nameDisplay="refametinib"/></Drugs><PaymentsToPrincipal><Payment><Reference id="1296038">1296038</Reference><Type>Other Milestones</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="2012 Q1" exchangeRateUS="1">7.5</USDAmountMil></Value></Payment></PaymentsToPrincipal><Summary>&lt;para&gt;In May 2012, Ardea  earned  a milestone payment of $7.5 million from Bayer,  triggered by the initiation of the phase II portion of a previously reported phase I/II clinical trial evaluating  BAY 86-9766 in combination with &lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt; for the treatment of advanced pancreatic cancer [&lt;ulink linkType="Reference" linkID="1296038"&gt;1296038&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Development Milestone</Type></Event></TimeLine><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="59014" type="Drug"><TargetEntity id="474103" type="siDrug">RDEA-436</TargetEntity></SourceEntity><SourceEntity id="56559" type="Drug"><TargetEntity id="444804" type="siDrug">Refametinib</TargetEntity></SourceEntity><SourceEntity id="17253" type="Company"><TargetEntity id="4295915893" type="organizationId">Ardea Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="1003983" type="Company"><TargetEntity id="4297658047" type="organizationId">Bayer HealthCare AG</TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"/><TargetEntity id="88673" type="ORPHANET"/><TargetEntity id="-1116061312" type="omicsDisease"/><TargetEntity id="1973" type="siCondition"/></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"/><TargetEntity id="10033609" type="MEDDRA"/><TargetEntity id="D010190" type="MeSH"/><TargetEntity id="-670361033" type="omicsDisease"/><TargetEntity id="630" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="4764" type="Action"><TargetEntity id="1227" type="Mechanism">Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 (MAP2K2; MEK2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4762" type="Action"><TargetEntity id="1226" type="Mechanism">Dual Specificity Mitogen-Activated Protein Kinase Kinase 1 (MAP2K1; MEK1) Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal></dealRecordsOutput>